Fundraising Fox

Odyssey Therapeutics

Cambridge, US · Founded 2021 · Delaware corporation · 126 employees on LinkedIn · 17 known investors

Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation. Its pipeline focuses on autoimmune and inflammatory diseases with large patient populations and unmet medical need.

BiotechMedical Devices

Founders & leadership

Odyssey Therapeutics was founded in 2021 by Gary D Glick.

GD
Gary D GlickinFounderExecutive Officer, Director at Scorpion Therapeutics

Board

JCJill Carroll
Jill CarrollinBoard directorOperating Partner - Portfolio Value Creation at SR One Capital Management
CGCarl Gordon
Carl GordoninBoard directorManaging Partner at OrbiMed
VO
Valerie OdegardBoard director
JL
Jeffrey LeidenBoard director
CB
Charles BaumBoard director

Investors · 17

Activant CapitalNew York · $100K – $50M
Balderton CapitalLondon · $5M – $50M
Catalio Capital Management, LPNew York
Foresite CapitalWest Hollywood
Global BioAccess FundNew York · $10M
GreatPoint VenturesSan Francisco · $250K – $20M
Jeito CapitalParis
Lightspeed Venture PartnersMenlo Park · $1.7M – $87M
OrbiMedNew York · $1M – $75M
Sanofi VenturesCambridge · $5M
SR One Capital ManagementRedwood Cityvia Jill Carroll · board
Ascenta CapitalreportedWilmington
Dimension Capitalreported · 3 sourcesSan Francisco · $1M – $10M

Also in the syndicate · 4

Affinity Asset AdvisorsLightspeed VenturesTPG Life Sciences InnovationsWedbush Healthcare Partners

Funding

SEC filings, press & company announcements

$590.9M disclosed across 4 of 5 rounds · 2021–2026

▶$214MraisedDec 2025 · 55 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Valerie OdegardDirector
  • Carl GordonDirector
  • Carolyn NgDirector
  • Gary D. GlickExecutive Officer, Director
  • Timothy WalbertDirector
  • Paulina HillDirector
  • Nan LiDirector
  • Jeffrey LeidenDirector
  • Jason HaasExecutive Officer
  • Nia TatsisDirector
  • Ksenija PavleticDirector
  • Shelley ChuDirector
  • lan F. SmithDirector
  • Jill CarrollDirector
Offering amount
$214M
Amount sold
$214M
First sale
Jun 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$117.2MraisedAug 2024 · 43 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Timothy WalbertDirector
  • Charles M. BaumDirector
  • Gary D. GlickExecutive Officer, Director
  • Jill CarrollDirector
  • Jeffrey LeidenDirector
  • Ian SmithDirector
  • Valerie OdegardDirector
  • Lorence KimDirector
  • Carl GordonDirector
Offering amount
$121.1M
Amount sold
$117.2M
First sale
Oct 2023
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$168MraisedOct 2022 · 34 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Valerie OdegardDirector
  • Jill CarrollDirector
  • Carl GordonDirector
  • Jeffrey LeidenDirector
  • Charles BaumDirector
  • Gary D GlickExecutive Officer, Director
Offering amount
$174.9M
Amount sold
$168M
First sale
May 2022
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$91.6MraisedOct 2021 · 63 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Carl GordonDirector
  • Chuck BaumDirector
  • Valerie OdegardDirector
  • Gary D GlickExecutive Officer, Director
  • Jill CarrollDirector
Amount sold
$91.6M
First sale
Aug 2021
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 1

by search overlap
Bioworld20 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.

Companies competing with Odyssey Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

In the news

Odyssey Therapeutics (ODTX) Looks Fully Valued As Earnings And Evotec Deal Refocus Attentionfinance.yahoo.com · Aug 2026Odyssey Therapeutics upsizes IPO to raise $304mbioxconomy.com · May 2026Odyssey Therapeutics Hits $900M Valuation In Nasdaq Debut, Stock Climbs 13% Before Diving Lowerstocktwits.com · May 2026Odyssey Therapeutics Announces Oversubscribed $213 Million Series D Financing to Advance Clinical Pipeline for Autoimmune Diseases - Odysseyodysseytx.com · Sep 2025Odyssey Therapeutics Raises $168M in Series B Financingfinsmes.com · Oct 2022Intellectiaintellectia.ai

Frequently asked questions

What does Odyssey Therapeutics do?
Odyssey Therapeutics develops small molecule and protein therapeutics targeting upstream signaling nodes and innate immune system mechanisms to prevent pathological inflammation. Its pipeline focuses on autoimmune and inflammatory diseases with large patient populations and unmet medical need.
Who founded Odyssey Therapeutics?
Odyssey Therapeutics was founded by Gary D Glick in 2021.
Who are Odyssey Therapeutics's investors?
Odyssey Therapeutics's investors include Activant Capital, Balderton Capital, Catalio Capital Management, LP, Foresite Capital, Global BioAccess Fund, GreatPoint Ventures, Jeito Capital, Lightspeed Venture Partners and 5 more.
How much funding has Odyssey Therapeutics raised?
Odyssey Therapeutics has disclosed $590.9M raised across 4 of its 5 known rounds.
Where is Odyssey Therapeutics headquartered?
Odyssey Therapeutics is headquartered in Cambridge, US.